SyntheticMR announces estimated net sales of SEK 12m. (21.2) for quarter 2 of 2024 depending on organizational changes in USA. The net sales target for 2024 is therefore not expected to be achieved

The costs for the second quarter are expected to be on a par with the same period last year, which therefore also applies to the entire first half of 2024. This outcome is the result of good cost control and efficiency improvements in operations globally. All figures are preliminary and unaudited. The full interim report for the second quarter will be published on August 27, 2024, as previously announced.

"We know from experience that our business sometimes has large fluctuations over the quarters. After four straight quarters of record sales, we have now been negatively affected by unforeseen events in the organization. This has led to a number of sales processes being hampered. The situation is isolated to the subsidiary in the USA. Other priority regions continue to develop well. Positive in this context is also that the response from the market in North America as well as globally for our offer is undiminished strong," says Ulrik Harrysson, CEO, SyntheticMR.

This disclosure contains information that SyntheticMR AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 09-07-2024 21:34 CET.